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ABSTRACT
Ovarian cancer is the most malignant and aggressive gynecological cancer. Due to nonspecific symptoms in the early stage 
and a lack of effective screening methods, it is typically diagnosed at an advanced stage. The high-grade serous cancer 
(HGSC) represents 75% of all ovarian cancers and accounts for the majority of deaths. Contemporary thought suggests that 
precursor lesions of HGSC originate in the fallopian tube. The presumed precursor tubal lesion, localized at the fimbrial end 
of the fallopian tubes, is termed the serous tubal intraepithelial carcinoma (STIC). Thus, removal of the fallopian tubes at 
the time of pelvic or abdominal surgery for a benign condition (i.e. opportunistic salpingectomy) appears as an attractive 
option for primary prevention of HGSC. This paper presents the scientific background of opportunistic salpingectomy and 
discusses controversies regarding the benefits and safety of the procedure.
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INTRODUCTION
Ovarian cancer is the seventh most common malignancy 
in women worldwide and the second most common gy-
necological malignancy in developed countries. Each year 
there are approximately 230 000 new cases diagnosed and 
about 140 000 patients die due to ovarian cancer worldwide 
[1]. In Poland, in the year 2010 there were 3 557 new regis-
tered cases of ovarian cancer. According to the prognosis of 
the Polish Union of Oncology for the year 2025, primarily due 
to aging of the population, the morbidity and mortality rates 
in ovarian cancer are expected to increase by 0.7% annually, 
with around 3800 new cases anticipated in the year 2025. 
Ovarian cancer is the most lethal gynecological malig-
nancy. Nonspecific symptoms in early stage of disease and 
a lack of effective screening methods are the main reasons 
why more than 70% of cases are diagnosed in FIGO stage 
III or IV. Despite the progress in therapy the mortality rate 
remains high with a five-year overall survival of only 20–40% 
for advanced disease [2, 3].
Recent histopathological, molecular and genetic studies 
resulted in recognition of dualistic model of carcinogenesis, 
which distinguish two broad categories of epithelial ovar-
ian cancer (EOC): low-grade (type I) and high-grade (type 
II) tumors. These two types differ significantly in terms of 
clinical behavior, genetic and molecular background as well 
as precursor lesions.
The most common histological subtype among type 
II tumors is the high-grade serous cancer (HGSC), which 
represents 75% of all ovarian cancers and accounts for the 
majority of deaths [4]. According to contemporary thought, 
precursor lesions of HGSC originate in the fallopian tube 
fimbria. In recent years, removal of the fallopian tubes at the 
time of pelvic or abdominal surgery for a benign condition 
(i.e. opportunistic salpingectomy) appeared as an attractive 
option for primary prevention of HGSC. The paper presents 
the scientific background of opportunistic salpingectomy 
and discusses controversies regarding the benefits and 
safety of the procedure.
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THE FALLOPIAN TUBE AS THE ORIGIN  
OF HIGH-GRADE SEROUS OVARIAN CANCER
It is hypothesized that the junction of the fallopian tube 
epithelium with the ovarian mesothelium might be a po-
tential site of carcinogenesis, similar to the uterine, cervical, 
gastroesophageal or anorectal junctions. Exposure of the 
fimbrial end to the locally elevated inflammatory cytokines 
at ovulation may trigger development of precursor lesions 
and malignant transformation by selection of p53 mutations 
in epithelial cells, which are clonally stimulated to expand 
[5–7]. In turn, telomere shortening occurs and enhances 
the basal epithelium for transformation and development 
of dysplasia. Shortening of telomeres is one of the earliest 
molecular alterations in carcinogenesis observed in many 
human pre-invasive epithelial lesions [8].
The initial evidence for the fallopian origin of ovar-
ian cancer came from the studies of prophylactic salpin-
go-oophorectomy in women bearing BRCA mutations. De-
tailed examination of fallopian specimens revealed dysplas-
tic lesions, later designated as serous tubal intraepithelial 
carcinoma (STIC) located in the fimbrial end. The prevalence 
of STIC in asymptomatic BRCA mutation carriers is estimated 
to be between 2% and 6% [9, 10].
It is worth emphasizing that precursor lesions have 
never been found in the ovarian epithelium.
The hypothesis that epithelial ovarian cancer originates 
from epithelium of the fallopian tubes is based on the logical 
sequence of events. P53 mutations are regarded as the earliest 
alterations that lead to formation of clusters of at least 12 se-
cretory cells with intense p53 immunoexpression and low 
proliferation index in morphologically normal fallopian tubes 
known as ‘p53 signatures’ [11]. These lesions, which can be 
identified histologically, were termed STIC [7, 12].
STIC is composed of non-ciliated (secretory) cells of 
the endosalpinx, which demonstrate characteristic features 
such as: variable combination of epithelial stratification (in-
cluding loss of cellular polarity and exfoliation of cells into 
the lumen), intraepithelial fracture lines, irregular luminal 
surface, cellular pleomorphism, irregular chromatin pattern, 
nuclear rounding and molding, increased nuclear-to-cyto-
plasmic ratio, mitotic figures, and apoptotic bodies without 
evidence of any stromal invasion [13, 14].
HGSC, ‘p53 signatures’ and STIC share identical p53 mu-
tations suggesting a link between precursor lesions and 
carcinoma. Mucosal tubal involvement, including STIC, was 
observed in over 70% of cases of ovarian and primary peri-
toneal HGSC [15].
Recently, another potential precursor lesion, termed 
secretory cell outgrowths (SCOUTs), have been identified. 
They were described as a succession of at least 30 epithe-
lial cells with a pseudostratified appearance [16]. SCOUTs 
do not bear p53 mutations, however, it is speculated that 
they act as a “precursor correlate” inducing alterations in 
p53-expressing benign lesions [7, 9].
There is growing evidence supporting the concept of 
the fallopian origin of ovarian HGSC. For instance, the gene 
expression profile of HGSC is closely related to fallopian tube 
epithelium rather than to the ovarian surface epithelium 
[17, 18]. HGSC express a mesothelial marker — PAX8 — but 
not claritin, a mesothelial marker typical for ovarian surface 
[5]. Moreover, a clonal relationship between STIC and con-
comitant HGSC can be proved by the presence of identical 
p53 mutations and co-expression of p16, FAS, Rsf-1 and 
cyclin E1 [19]. Finally, a study on a mouse model showed 
that the removal of the fallopian tubes, but not removal of 
the ovaries, prevents HGSC formation [9, 20, 21].
The precise mechanism of fallopian cell implantation 
into the ovary remains to be elucidated. It is likely that rup-
ture of the dominant follicle at the time of ovulation exposes 
the underlying ovarian stroma to fimbrial epithelium. Thus, 
the progenitor lesions may implant on the ovarian surface 
or invaginate into the ovarian stroma [5–7,10, 22–25].
The detection rate of fallopian precursor lesions can be 
increased by detailed examination of the fimbrial end. To 
address this issue a protocol for Sectioning and Extensively 
Examining the FIMbria (SEE-FIM protocol) has been de-
veloped. In the first step, the distal 2 cm of fimbrial end is 
transected and then sectioned longitudinally in as many 
sections as practical. Finally, the remaining part of the tube 
is sectioned with 2–3 mm intervals and combined with the 
sectioned fimbrial end [25].
ENDOMETRIOSIS AS A PRECURSOR LESION 
FOR TYPE I ENDOMETRIOID AND CLEAR CELL 
OVARIAN CARCINOMA
Several epidemiological and molecular studies imply 
a link between endometriosis and low-grade endometri-
oid and clear cell ovarian carcinoma. A meta-analysis con-
ducted by Kumar et al. showed that endometriosis increases 
overall ovarian cancer risk, but endometriosis-associated 
cancers are characterized by early-stage, low-grade and 
endometrioid or clear cell histology [26]. Similarly Pearce 
et al. performed an analysis of 13 studies and found that 
self-reported endometriosis is associated with an increased 
risk of clear-cell (Odds ratio (OR) 3.05) and endometrial (OR 
2.21) ovarian cancer. Endometriosis associated ovarian can-
cer (EAOC) is defined as a type of neoplasm that coincides 
with endometriosis in the same or in the contralateral ovary, 
or with coexisting pelvic endometriosis. It was estimated 
that coincidence of endometriosis and carcinoma in the 
same ovary occurs in 35.9% of cases for clear cell and 19% 
of cases for endometrioid type cancer [27–29]. Although 
there is no uniform theory of endometriosis pathogenesis, 
retrograde menstruation is likely to account for develop-
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ment of most cases. Consequently, endometrioid and clear 
cell ovarian carcinoma seem to arise from endometrial tis-
sue implanted on the ovary. This hypothesis is supported 
by observations that tubal ligation decreases the risk of 
ovarian cancer, but only in cases of endometrioid and clear 
cell types [6, 30–32].
OPPORTUNISTIC SALPINGECTOMY  
AS A PRIMARY PREVENTION STRATEGY
Given the accumulating evidence indicating that serous, 
endometrioid and clear cell epithelial ovarian carcinomas 
do not originate directly from the ovary, salpingectomy 
performed at the time of pelvic or abdominal surgery for 
benign condition is an attractive option for primary preven-
tion of ovarian malignancies. Presumably, this procedure 
may also prevent the development of mucinous and Brenner 
ovarian cancer, the pathogenesis of which has been linked 
to remnants of paratubal cysts (or Walthard cell nests) and 
primary fallopian tube cancer [6, 7]. Additional benefits of 
salpingectomy may include prevention of tubal pathologies 
such as pyosalpinx or hydrosalpinx formation [33, 34]. Sev-
eral scientific societies and opinion boards advocate consid-
eration of the removal of the fallopian tubes during hyster-
ectomy or other pelvic surgery in women who accomplished 
reproduction, where there is surgical access. Although, the 
fimbria is the preferred site, precancerous lesions have also 
been identified in the ampulla [20]. Therefore, the whole 
tube should be removed, if possible.
To date, there are no prospective studies evaluating the 
efficacy of opportunistic salpingectomy, thus a potential 
reduction in the incidence of epithelial ovarian carcinoma 
and related healthcare benefits are based on theoretical 
knowledge alone. Kwon et al., using the Monte Carlo simu-
lation model, calculated that salpingectomy added to hys-
terectomy would reduce the ovarian cancer risk by 38.1% 
and when performed instead of tubal ligation by 29.2%. 
However, the absolute benefit may be less evident since the 
number of cases of ovarian cancer among hysterectomized 
women would decrease from 270 to 167 cases per year [35]. 
A population-based study from Sweden showed a statisti-
cally significant 35% lower risk for ovarian cancer among 
women with previous salpingectomy when compared to 
the unexposed population [36]. Less optimistic estimations 
have been derived for the German population, based on 
the assumption that all serous carcinomas originate from 
the fallopian tube and all hysterectomies would be com-
bined with bilateral salpingectomy; this analysis predicted 
a reduction in the incidence of all ovarian cancers by only 
2.3% over a period of 20 years [37]. A recent meta-analysis 
revealed that bilateral salpingectomy could reduce the risk 
of ovarian cancer by half (OR, 0.51) in the general population. 
However, taking into account that only 29 out of 3 509 pa-
tients in the salpingectomy group developed cancer, the real 
number of women who may benefit from the procedure is 
low [38]. On the other hand, human papillomavirus (HPV) 
vaccination, which is generally accepted as a primary pre-
vention of cervical cancer, requires exposure of 324 women 
to avoid one case of malignancy [39].
Salpingectomy appears safer and less harmful than sal-
pingo-oophorectomy (SO). Removal of the ovaries before 
the age of 65 years is thought to increase the risk of car-
diovascular disease, osteoporosis or cognitive impairment 
[40–43].
Opportunistic salpingectomy is not associated with sig-
nificant perioperative risks. The average additional operating 
time required for salpingectomy was 16 minutes when added 
to hysterectomy, and 10 minutes when done instead of tubal 
ligation. Although statistically significant, these differences 
are of a little clinical significance. There is no increased risk 
of blood transfusion, prolonged hospitalization or rate of 
hospital readmission associated with salpingectomy. Simi-
larly Minig et al. and Morelli et al. demonstrated that when 
salpingectomy was added to laparoscopic hysterectomy, 
there was no difference in operating time, postoperative 
hemoglobin, hospital stay, or complication rates. Even wide 
salpingectomy with excision of the mesosalpinx did not alter 
the perioperative blood loss, postoperative vital signs and 
patients’ subsequent activities [39–42]. Chene et al. showed 
that salpingectomy could be safely performed in most (73.9%) 
patients undergoing vaginal hysterectomy. There was only 
one case of postoperative hemorrhage among 51 patients 
after salpingectomy. Of interest, the prevalence of immuno-
histochemical abnormalities in the p53 protein phenotype 
in the removed tubes reached 12.9%.
DOES SALPINGECTOMY INFLUENCE 
OVARIAN FUNCTION?
It is unlikely that salpingectomy negatively affects ovar-
ian function. In animal models salpingectomy conducted 
simultaneously with hysterectomy did not alter ovarian vol-
ume, blood flow or follicle count. Morelli et al. showed that 
the addition of bilateral salpingectomy to total laparoscopic 
hysterectomy for prevention of ovarian cancer in women 
who do not carry a BRCA1/2 mutation did not impose nega-
tive effects on ovarian function. Serum concentrations of 
anti-Müllerian hormone (AMH) and follicle-stimulating hor-
mone (FSH) remained stable shortly after tubal removal and 
in the 3-month follow-up period. No significant changes 
were observed in antral follicle count, ovarian diameter 
or peak systolic velocity [41–44]. In concert, Findley et al. 
confirmed a lack of detrimental effects associated with sal-
pingectomy on AMH levels, even if surgical excision includes 
the removal of the mesosalpinx, the ovarian reserve is not 
damaged. Moreover, wide salpingectomy does not alter 
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Table I. Statements of gynecological boards on opportunistic salpingectomy
Board Recommendation
Royal College of Obstetricians and Gynaecologists [47]
Women who are not at high risk for BRCA mutation and have 
completed their families should be carefully considered for prophylactic 
removal of the fallopian tubes with conservation of ovaries at the time 
of gynaecological or other intraperitoneal surgery
American College of Obstetricians and Gynecologists [48]
The surgeon and patient should discuss the potential benefits of the 
removal of the fallopian tubes during a hysterectomy in women at 
population risk of ovarian cancer who are not having an oophorectomy
Prophylactic salpingectomy may offer clinicians the opportunity to 
prevent ovarian cancer in their patients
Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists [49]
Doctors should discuss the risks and benefits of bilateral salpingectomy 
with patients undergoing hysterectomy for benign disease
Society of Gynecologic Oncology [50]
For women at average risk of ovarian cancer, risk-reducing 
salpingectomy should also be discussed and considered with patients 
at the time of abdominal or pelvic surgery, hysterectomy or in lieu of 
tubal ligation
Kommission Ovar of the AGO [50]
During preoperative counselling prior to hysterectomy, all patients 
should be informed about the potential beneficial impact of 
opportunistic salpingectomy and the associated risks
Committee on Gynecologic Practice [51]
Current attempts at screening for ovarian cancer have been 
unsuccessful and are associated with false-positive test results that 
lead to unnecessary surgery and surgical complications. Prophylactic 
salpingectomy may offer clinicians the opportunity to prevent 
ovarian cancer in their patients. Randomized controlled trials are 
needed to support the validity of this approach to reduce the incidence 
of ovarian cancer
Figure 1. Fallopian tube specimen prepared by authors according to the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM 
protocol). The directions of sections of the fimbrial end and remaining part of the tube are indicated on (A)
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blood loss during surgery, hospitalization stay or patients’ 
return to normal activities [45, 46].
CONCLUSION
It has been described that opportunistic salpingectomy 
is a procedure of unproven efficacy. All data supporting the 
use of this procedure is derived from molecular, pathological 
and animal studies. Taken together, these data form the basis 
of a new theory or paradigm of ovarian cancer pathogen-
esis. The potential for randomized studies seems unrealistic 
and does not give the opportunity to resolve the issue for at 
least 20 years. On the other hand, salpingectomy performed 
at the time of other pelvic surgeries is a simple, costless 
procedure characterized by minimal, if any, morbidity. Many 
scientific societies and advisory boards recommend, or at 
least advocate, removal of fallopian tubes in women un-
dergoing pelvic surgery who accomplished reproduction. 
Taking into account that high-grade serous ovarian cancer is 
a highly lethal disease, this procedure is worth considering 
as a potentially efficient preventive method.
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